Omeros Corporation (NASDAQ:OMER – Get Free Report) was the recipient of unusually large options trading on Tuesday. Traders bought 11,366 put options on the stock. This represents an increase of 247% compared to the average daily volume of 3,275 put options.
Omeros Stock Performance
OMER opened at $10.37 on Thursday. The stock’s 50 day moving average price is $10.87 and its 200-day moving average price is $11.81. The stock has a market cap of $750.53 million, a price-to-earnings ratio of 14.81 and a beta of 2.55. Omeros has a one year low of $3.34 and a one year high of $17.65.
Omeros (NASDAQ:OMER – Get Free Report) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The business had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $4.19 million. As a group, analysts predict that Omeros will post -0.94 earnings per share for the current fiscal year.
Insider Activity at Omeros
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares in the last quarter. UBS Group AG lifted its holdings in shares of Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after buying an additional 1,513,893 shares during the period. Geode Capital Management LLC grew its position in shares of Omeros by 6.3% during the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock worth $28,026,000 after buying an additional 95,979 shares in the last quarter. State Street Corp increased its stake in shares of Omeros by 26.9% during the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock valued at $27,025,000 after buying an additional 333,798 shares during the period. Finally, Two Sigma Investments LP increased its stake in shares of Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock valued at $3,827,000 after buying an additional 263,095 shares during the period. Institutional investors own 48.79% of the company’s stock.
Analyst Ratings Changes
A number of research firms recently weighed in on OMER. Wall Street Zen cut shares of Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, June 7th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Tuesday, April 21st. HC Wainwright decreased their target price on Omeros from $40.00 to $33.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Finally, Weiss Ratings lowered Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.00.
Get Our Latest Stock Analysis on OMER
Omeros Company Profile
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Articles
- Five stocks we like better than Omeros
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
